Eligo inks deal with GSK potentially worth up to $224M

PARIS, Jan. 11, 2021 /PRNewswire/ — Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing EligobioticsĀ® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based…

About the Author

has written 41562 stories on this site.

Copyright © 2010 Business and Corporate News.